OS
Fig. 2. · Panel BRCA-mutated_carcinoma_population
Panel BRCA-mutated_carcinoma_population 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Jonathan A Ledermann, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew R Clamp, Giovanni Scambia, Alexandra Leary, Robert W Holloway, Margarita Amenedo Gancedo, Peter C Fong, Jeffrey C Goh, David M O'Malley, Deborah K Armstrong, Susana Banerjee, Jesús García-Donas, Elizabeth M Swisher, Coriolan Lebreton, Gottfried E Konecny, Iain A McNeish, Clare L Scott, Lara Maloney, Sandra Goble, Kevin K Lin, Robert L Coleman
Eur J Cancer 225 115584
BACKGROUND: In ARIEL3, rucaparib maintenance significantly improved progression-free survival (PFS; primary endpoint) and long-term follow-up (LTFU) outcomes (including PFS2: time to disease progression on subsequent therapy or death) versus placebo in patients with recurrent, platinum-sensitive ovarian cancer. Here we report the final analysis of overall survival (OS; key secondary endpoint), LTFU outcomes, and safety. METHODS: OS and updated LTFU efficacy outcomes were analyzed (data cutoff date: April 4, 2022) across three nested populations (BRCA-mutated, homologous recombination deficient [HRD], and intention to treat [ITT]). RESULTS: Patients were randomized 2:1 to rucaparib (600 mg BID; n = 375) or placebo (n = 189). Median follow-up was 77.0 months. 168 patients in the placebo arm received subsequent treatment; of these, 77 (46 %) received a poly(ADP-ribose) polymerase inhibitor-containing treatment. Median OS from randomization post chemotherapy for rucaparib vs placebo was 45.9 vs 47.8 months (HR 0.83, 95 % CI 0.58-1.19) for the BRCA-mutated population; no OS benefit was found with rucaparib in the HRD and ITT populations. Median PFS2 for rucaparib vs placebo was 26.1 vs 18.4 months (HR 0.67, 95 % CI 0.48-0.94) for the BRCA-mutated population. Rucaparib numerically improved PFS2 and other LTFU outcomes versus placebo in the HRD and ITT populations. Safety was consistent with prior reports; myelodysplastic syndrome and/or acute myeloid leukemia occurred in 4 % and 3 % of patients in the rucaparib and placebo arms, respectively. CONCLUSIONS: OS was similar between treatment arms. PFS benefit with rucaparib was maintained through the subsequent therapy line. These data support rucaparib as maintenance treatment for recurrent ovarian carcinoma.
2 个 Figure · 6 个 KM 面板
Fig. 2. Kaplan–Meier curves for OS in nested populations. Abbreviations: BRCA , BRCA1 or BRCA2 ; CI, confidence interval; HR, hazard ratio; HRD, homologous recombination deficient; ITT, intention to treat; LOH, loss of heterozygosity; OS, overall survival. *Includes BRCA -mutated carcinoma and BRCA wild-type/LOH-high groups.
Fig. 2. · Panel BRCA-mutated_carcinoma_population
Panel BRCA-mutated_carcinoma_population 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2. · Panel HRD_carcinoma_population_
Panel HRD_carcinoma_population_ 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2. · Panel ITT_population
Panel ITT_population 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4. Kaplan–Meier curves for PFS2 in nested populations. Abbreviations: BRCA, BRCA1 or BRCA2; CI, confidence interval; HR, hazard ratio; HRD, homologous recombination deficient; ITT, intention to treat; LOH, loss of heterozygosity; PFS2, time to disease progression on subsequent therapy or death. *Includes BRCA-mutated carcinoma and BRCA wild-type/LOH-high carcinoma groups.
Fig. 4. · Panel BRCA-mutated_carcinoma_population
Panel BRCA-mutated_carcinoma_population 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4. · Panel HRD_carcinoma_population_
Panel HRD_carcinoma_population_ 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4. · Panel ITT_population
Panel ITT_population 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。